PPARG and diabetes mellitus: In the specific case of dihydrochalcone derivatives, given their ability to manage the glucose level in cells, in silico studies were focused on the main protein disease and molecular targets involved in diabetes: e.g., α-glucosidase, Aldose Reductase (ALR), Glucose Transporter Type 4 (GLUT4), Sodium Glucose Cotransporter 2 (SGLT2), Dipeptidyl Peptidase 4 (DPP-4), Protein Tyrosine Phosphatase 1B (PTP1B), Peroxisome Proliferator-activated Receptor-gamma (PPARγ) and Adenosine Monophosphate (AMP)-activated Protein Kinase (AMPK) [36].